Worm.com

TELECOMWORLDWIRE-8 July 2008-Check Point expands UTM-1 range of security gateway systems(C)1994-2008 M2 COMMUNICATIONS LTD http://www.m2.com

Check Point Software Technologies Ltd (Nasdaq:CHKP), a company providing network security solutions, announced on 7 July the addition of two new appliances to its UTM-1 Total Security range.

The two new models (the 1070 and the 2070) join the UTM-1 range of appliances designed to provide customers with a single security solution loaded with a firewall and virtual private networking (VPN) capabilities including secure sockets layer (SSL) encryption functions. The systems also boast intrusion detection, anti-virus, anti-spyware, web filtering and security and anti-spam features.

The 1070 is capable a 1800Mb/s throughput and can support up to three managed sites, while the 2070 has a maximum throughput of 2800Mb/s and can support five managed sites. The 1070 is equipped with six ports and the 2070 eight ports.

Prices for UTM-1 Total Security products start at USD4,800.

((Comments on this story may be sent to tww.feedback@m2.com))

COPYRIGHT 2008 M2 Communications Ltd.
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

New offering enables partners to reach more customers and boost sales.

HOUSTON, July 8 /PRNewswire-FirstCall/ — Stephen Elop, president of the Microsoft Business ivision, today announced new pricing, packaging and partner compensation details for Microsoft Online Services. Microsoft Corp. is introducing two new suites of subscription services as part of the Microsoft Online Services family. The new offerings are tailored to meet the needs of the entire work force — from employees who use a PC infrequently to information workers who require advanced capabilities.

(Logo: http://www.newscom.com/cgi-bin/prnh/20000822/MSFTLOGO)

"Today we are taking an important next step in delivering Microsoft Online Services, and we’re doing so with a broad set of Microsoft partners, that are crucial to bringing this solution to our customers," Elop said at the annual Microsoft Worldwide Partner Conference in Houston. "Microsoft Online Services is a key component of the software plus services initiative, and we’re seeing customers, partners and even competitors embrace this flexible approach to the cloud."

Microsoft Online Services delivers enterprise-class Microsoft software as subscription services to businesses of all sizes hosted by Microsoft and sold with partners, and include Microsoft Exchange Online, Microsoft Office SharePoint Online, Microsoft Office Communications Online, Microsoft Office Live Meeting, and Microsoft Dynamics CRM Online.

The Right Features at the Right Price

Microsoft Online Services is priced to meet the diverse needs of today’s workers and provide businesses with a cost-effective means to equip their work force with the tools they need.

Microsoft is introducing Exchange Online Deskless Worker and SharePoint Online Deskless Worker. These new offerings are designed to meet the needs of deskless workers, those people who typically spend a small portion of their workday using a computer but still need to communicate and collaborate with colleagues and partners.

A Deskless Worker Suite, including Exchange Online Deskless Worker and SharePoint Online Deskless Worker, will be available for $3 (U.S.) per user, per month. Customers can also subscribe to each service independently. Exchange Online Deskless Worker will provide e-mail, calendars, global address lists, anti-virus and anti-spam filters, as well as Outlook Web Access Light for access to company e-mail. SharePoint Online Deskless Worker will provide easy access to SharePoint portal and team sites and search functionality, giving employees read-only access to important information such as company policies, training and benefits.

For information workers, businesses can provide an online business productivity suite of Microsoft’s enterprise-class communication and collaboration software as a subscription service. The suite includes the following:

  --  Exchange Online for desktop and mobile e-mail and calendars with
      Outlook Web Access and full Office Outlook integration
  --  Office SharePoint Online for portals, collaboration, search and
      customized team sites
  --  Office Communications Online for instant messaging and presence
  --  Office Live Meeting for Web conferencing and videoconferencing

The suite will be available for $15 per user, per month (U.S.). Customers can also subscribe to each service independently.

"Microsoft Online Services is the right solution for our business, as the subscription model enables us to provide our employees with the right software on a variable-cost basis," said Marv Toland, chief financial officer for Eddie Bauer. "This helps Eddie Bauer meet the needs of its employees by ensuring that we are continually upgraded to the most current releases. With Microsoft running these services, our IT department is able to focus on strategic, value-enhancing projects. We believe that this is the model for the future."

Partner Compensation Model

Microsoft Online Services creates a new opportunity for Microsoft partners to win new customers, increase revenue and boost sales velocity. Partners are seeing new opportunity to migrate, combine and customize Microsoft Online Services. In addition, partners that sell Microsoft Online Services will receive a recurring revenue stream for as long as their customer subscribes to the services.

"Microsoft is committed to software plus services, and we are equally committed to embracing this opportunity together with the Microsoft partner community," said Allison L. Watson, corporate vice president of the Worldwide Partner Group at Microsoft. "The success of Microsoft Online Services depends on the partners that sell, customize and provide consulting, migration and managed services for customers. The end result is an environment where both customers and partners win. Partners will have a tremendous opportunity in the midmarket, where customers can get enterprise-class software delivered on a predictable, pay-as-you-go basis."

Information provided by: Findarticles.com

Today at Game On!

Picking the U.S. Olympic teams

The U.S. Olympic teams are set for swimming and track and field after grueling trials, but did it really need to be that rough on the athletes?

Traditionally, the thinking is having all-or-nothing trials for swimming and track leaves the U.S. with rosters that are better prepared for the all-or-nothing competition at the Olympics.

But would we be unified behind that philosophy if, say, Michael Phelps had been hit with a virus that sidelined the world’s greatest swimmer?

The track trials, where injuries are more common, have more often been the competition …

Information provided by: Findarticles.com

VIENNA, Austria, July 8 /PRNewswire/ — Avir Green Hills Biotechnology starts a clinical phase I study with its intranasal vaccine deltaFLU against pandemic influenza. This novel generation of a live-attenuated vaccine based on the deletion of the NS1 gene has shown superior preclinical data. In taking this step, the Viennese biotech company sets yet another milestone in the development of effective and safe vaccines.

Aim of Phase I Study

The randomized, double-blind phase I study of the pandemic vaccine deltaFLU will be run at the Department of Clinical Pharmacology, Medical University of Vienna. The aim of phase I study is to analyze the safety and efficacy of the vaccine in healthy volunteers.

Preclinical Data, Pandemic Vaccine

"Our vaccine lacks the pathogenicity factor NS1. Due to this deletion, the vaccine is likely to show a superior safety profile. We are confident that the pandemic deltaFLU vaccine will be tolerated even at high doses," comments Thomas Muster, founder and CEO/CSO of Avir Green Hills Biotechnology.

Outstanding preclinical data show an excellent immune response even against distantly related pandemic H5 strains (cross-protection). Moreover, a long lasting immune response - an important prerequisite for an effective vaccine - was observed.

"We are very pleased about the success of our vaccine in the preclinical studies. The data are superb and exceed our highest expectations," reports Andrej Egorov, who is Vice President for Research at Avir Green Hills Biotechnology and one of the leading experts in the field of live attenuated influenza vaccines.

The novel influenza vaccine deltaFLU

differs from a conventional influenza vaccine in three major characteristics and in the method of production:

1. Nasal Spray

The vaccine is administered intranasally with a spray device instead of being injected into a muscle. This approach offers the major advantage of stimulating the vaccine protection directly at the site of virus entry.

2. Effective Immune Response

Though the vaccine looks like a pathogenic influenza virus to the body, it does not cause disease. However, after intranasal application, the vaccine stimulates a strong immune response, which offers protection against influenza. In other words, the vaccine "fakes" an infection that induces an immune response without causing illness.

3. Cross-Protection

The vaccine can induce an effective immune response against a wide range of influenza virus variants, which is only conditionally possible with conventional vaccines. This cross-reactivity can also provide protection against distantly related "drift variants" of pandemic influenza strains.

4. Cell-Based Production Method

The technology used by Avir Green Hills Biotechnology comprises a modern production method in cell cultures and does not rely on traditional egg-based manufacturing. In addition, Avir Green Hills Biotechnology has optimized the method of reverse genetics, which permits the generation of a vaccine against any potential influenza virus within a very short period of time. This might be essential for a timely response in pandemic situations.

Avir Green Hills Biotechnology Inc.

Avir Green Hills Biotechnology Inc. is a biopharmaceutical company based in Vienna, founded in 2002. Avir Green Hills Biotechnology’s core competence is the development of innovative, therapeutic and prophylactic products against viral infections and cancer. "Our strength is our extensive know-how in virology and our network of renowned national and international partners in academia and industry," says Joachim Seipelt, Co-Founder and Vice President for Cooperation at Avir Green Hills Biotechnology.

After completion of phase I clinical trials, Avir Green Hills Biotechnology will start clinical phase II studies with the pandemic and the seasonal deltaFLU vaccines in 2009. Subsequently, Avir Green Hills Biotechnology plans to perform a phase III challenge trial against seasonal influenza, which will allow early proof of efficacy. These studies will provide the basis for phase III field trials leading to market authorization.

  Press photos & movies
  http://www.greenhillsbiotech.com/news.html

  Contact
  Isolde Bergmann (Corp. Communications)
  mobile: +43-664-8573403
  mail: i.bergmann@greenhillsbiotech.com

  Avir Green Hills Biotechnology AG
  Gersthofer Strasse 29-31
  A-1180 Vienna
  Austria - Europe
  http://www.greenhillsbiotech.com/

CONTACT: Contact: Isolde Bergmann (Corp. Communications), mobile: +43-664-8573403, mail: i.bergmann@greenhillsbiotech.com. Avir Green Hills Biotechnology AG, Gersthofer Strasse 29-31, A-1180 Vienna, Austria - Europe

COPYRIGHT 2008 PR Newswire Association LLC
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com

Vivalis (NYSE Euronext : VLS) announced today that it has granted ACAMBIS INC. (LSE : ACM) rights to the avian embryonic stem cell derived eb66® cell line to evaluate it as a production platform of viral vectors and vaccines.

“Vivalis is pleased to enter in this agreement to support ACAMBIS’ R&D efforts for the development of new vaccines. With already more than 30 different vaccines evaluated or developed on VIVALIS eb66® cell line, we strongly believe that this cell line has the potential to replace the eggs, and to become a standard cell substrate for vaccines production in the foreseeable future”, said Franck GRIMAUD, Vivalis CEO.

Terms of the agreement were not disclosed.

*******************

Next press release:

13 August 2008, after closure of the Euronext Paris market: Turnover for the 2nd quarter of 2008

___________________________________________________________________

About Acambis ( www.acambis.com )

Acambis (Cambridge, UK and Cambridge, MA, USA) is a vaccine company developing novel vaccines that address significant unmet medical needs or substantially improve standards of care. It has a broad pipeline of novel vaccine candidates, including:

- the only single-dose vaccine in development against Japanese encephalitis;

- the leading vaccine in development against the West Nile virus;

- a tetravalent dengue vaccine that has achieved proof-of-concept by generating 100% seroconversion to all four dengue virus serotypes;

- the only vaccine in development against Clostridium difficile bacteria, a leading case of hospital-acquired infections;

- a novel influenza vaccine that provides a universal approach to tackling ‘A’ strains of the virus; and

- a replication-deficient vaccine, dl5-29, against genital herpes.

Acambis has partnerships with sanofi pasteur for the development and commercialisation of its JE, West Nile and dengue vaccines. It is recognised internationally as the leading producer of smallpox vaccines for emergency-use stockpiles held by the US Government and several other governments around the world. Acambis developed its ACAM2000(TM) smallpox vaccine under contracts with the US Government.

Acambis Inc. is the US-based subsidiary of Acambis plc, which is based in Cambridge, UK and Cambridge, Massachusetts, US, and is listed on the London Stock Exchange (ACM). More information is available at www.acambis.com .

About VIVALIS ( www.vivalis.com )

VIVALIS (NYSE- Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of viral diseases. VIVALIS’s expertise and intellectual property are exploited in three main areas:

1. The development and manufacturing of vaccines. VIVALIS offers research and commercial licenses for its EB66® cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of viral vaccines. Vivalis receive up front, milestones and royalties payments on its licensees net sales.

2. The development of production systems for recombinant proteins and monoclonal antibodies. VIVALIS licenses its EB66® cell line for the production of recombinant proteins to biotechnology and pharmaceutical companies. Vivalis receive up front, milestones, and royalties payments on its licensees net sales.

3. The construction of a portfolio of proprietary products in the area of vaccines and anti-viral molecules (hepatitis C).

Based in Nantes (France), VIVALIS was founded in 1999 by the Grimaud group (1,450 employees), the second largest group worldwide in animal genetic selection. VIVALIS has established numerous partnerships with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Novartis Vaccines, Kaketsuken, Merial and SAFC Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES bio-cluster.

Euronext Paris Compartment C - FR0004056851

Reuters: VLS.PA - Bloomberg: VLS FP

This information is provided by HUGIN

Investor relations:

VIVALIS
Franck Grimaud, C.E.O.
Email: investors@vivalis.com

NewCap
Financial Communication Agency
Steve Grobet / Emmanuel Huynh
Tel.: +33 (0) 1 44 71 94 91
Email: vivalis@newcap.fr

Information provided by: Findarticles.com

MOSCOW (AFP) — Russia faces an increase in disease, drought and damage to infrastructure because of climate change, the environmental group WWF said on Tuesday, urging the authorities to “take a lead” on the issue.

“We’re very worried…. We have to act in time. Some regions of Russia need urgent attention,” Alexei Kokorin, a WWF researcher and one of the authors of the report, said at a press conference in Moscow presenting a new study.

Drawing attention to an issue that is only beginning to be discussed in Russia, WWF said the authorities should press to reduce global emissions and adopt a strategy for dealing with the effects of climate change.

“We must understand that damage caused by climate change is here and now rather than a problem in the distant future…. There’s a lot at stake, including our health,” said Igor Chestin, head …

Information provided by: Findarticles.com

96-week comparative study of Clevudine versus Viread(R) versus Clevudine+Viread(R) in 150 patients with chronic hepatitis B

PRINCETON, N.J., July 8 /PRNewswire-FirstCall/ — The French National Agency for Research on AIDS and Viral Hepatitis (ANRS), with the support of Pharmasset, Inc. and Gilead Sciences, Inc. , has initiated the first head-to-head study of clevudine and Viread(R) (tenofovir disoproxil fumarate) administered separately, versus their combination, for the treatment of chronic hepatitis B virus (HBV) infection in non-cirrhotic patients. The study treatments include clevudine 30mg/day, tenofovir 300mg/day or the combination of both drugs administered to 150 treatment-naive hepatitis B e-antigen negative HBV-infected patients for 96 weeks. At that time, all therapy will be discontinued, and patients will be monitored for sustained virologic response (SVR) after being off of therapy for 24 weeks, the primary endpoint of the study.

Clevudine is an oral, once-daily pyrimidine nucleoside analog that has been evaluated in 18 clinical trials in more than 800 individuals. Phase 3 studies are currently being conducted in approximately 140 global clinical sites to support the registration of clevudine in the Americas and Europe. Pharmasset licensed clevudine for these territories from Bukwang Pharm. Co., Ltd, who has received South Korean regulatory approval and is currently marketing clevudine in South Korea under the brand name Levovir.

"Clevudine’s unique mechanism of action as a non-chain terminating nucleoside analog HBV polymerase inhibitor may demonstrate additive antiviral benefit in combination with tenofovir’s recently demonstrated antiviral potency in HBV," stated Dr. Michelle Berrey, Pharmasset’s Chief Medical Officer. "We also plan to reproduce the results from earlier studies demonstrating clevudine’s ability to provide a sustained virologic response in patients with eAg negative chronic HBV infection, as either monotherapy or in combination, offering infected individuals and their physicians an important new treatment option."

Ongoing Registration Studies for New Drug Application (NDA)

The ongoing clevudine Phase 3 registration program includes two 48-week clinical trials designed to demonstrate the superiority of clevudine 30mg over Hepsera(R) (adefovir dipivoxil) 10mg, each administered once-daily as monotherapy. Pharmasset plans to submit the 48-week data from these studies to the FDA as the basis for the clevudine marketing approval. Please see http://www.clinicaltrials.gov/ or e-mail clinicaltrials@pharmasset.com for more information about the clevudine registration studies.

South Korean Registration Studies for Clevudine

Bukwang received marketing approval for clevudine from the South Korean FDA based on two 24-week, placebo-controlled, double-blind, randomized, multi-center South Korean Phase 3 registration trials in 337 patients. Study 301 enrolled 248 HBeAg+ patients who received clevudine 30 mg or a placebo once-daily, and Study 302 enrolled 89 HBeAg- patients who received clevudine 30 mg or a placebo once-daily. All patients were evaluated for an additional 24 weeks of follow-up care without clevudine treatment.

At 24 weeks on treatment with clevudine, 59% of HBeAg+ patients achieved undetectable HBV DNA and 92% of HBeAg- patients achieved undetectable HBV DNA. These results were statistically significant compared to placebo. In addition to the potent antiviral suppression, 16% of the HBeAg- patients who received clevudine demonstrated a sustained virologic response (SVR) 24 weeks after stopping therapy, versus 0% of the patients who had received the placebo. In Study 303, a South Korean open-label, follow-on study of clevudine, Bukwang observed similar findings. 80% of HBeAg- patients had undetectable HBV DNA 12 weeks after completing a 48-week course of therapy.

Clevudine was generally safe and well-tolerated by patients with chronic HBV. There was no meaningful difference between clevudine and placebo in the incidence of serious adverse events during treatment in Studies 301 and 302 and during follow-up except that a higher percentage of placebo-treated patients had elevated liver enzyme levels than patients treated with clevudine.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset’s primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is in Phase 3 clinical trials for registration in the Americas and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a Phase 1/2 clinical trial through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Information provided by: Findarticles.com

ROCKVILLE, Md., July 8 /PRNewswire/ — Triumfant(R), the industry leader in continuous monitoring and control software, today announced that the U.S. District Court for the District of Maryland has purchased Triumfant Resolution Manager(TM). Resolution Manager automatically identifies and fixes problems in desktops, laptops and servers before the problems become service desk calls and adversely impact user productivity.

Triumfant Resolution Manager(TM) is the only solution that automatically detects and repairs both familiar and unknown issues such as configuration errors, malware and IT policy violations that can become problems and cause disruptions in an organization’s computing environment. Resolution Manager recommends fixes to each problem identified and can be set to automatically remediate and alert IT management when the fix is complete. By eliminating the dependence on cumbersome manual processes, Resolution Manager allows organizations to increase control of their IT environment, save an average of one-third in IT support costs and reduce end-user downtime.

"Missing files and drivers, unauthorized and incompatible software downloaded by a user, or a new virus are just a handful of the reasons why calls to IT support staff are growing exponentially," said John Prisco, CEO of Triumfant. "Using traditional, manual methods to troubleshoot and resolve these issues can take hours of support staff time and negatively impact productivity. By being able to identify and automatically resolve issues before the user even notices them, Triumfant Resolution Manager allows IT staff to focus on strategic initiatives rather than reactive problem solving."

About Triumfant

Triumfant is the leading provider of continuous monitoring and control software for Windows computers. Powered by the Triumfant IT Intelligence(TM) platform, Triumfant’s suite of solutions automates the process of discovering, diagnosing and repairing unwanted changes to every Windows PC, laptop and server. By ensuring strict adherence to internal controls, Triumfant helps organizations to reduce costs, minimize security and compliance risks, and increase quality of service. For more information or to download a free trial or schedule a pilot, visit http://www.triumfant.com/ .

Triumfant, Triumfant Resolution Manager, Triumfant IT Intelligence and the Triumfant logo are the exclusive properties of Triumfant, Inc. and are registered with the U.S. Patent and Trademark Office.

CONTACT: John Jordan of Principor Communications for Triumfant, +1-202-595-9008 x63, jjordan@principor.com

Web site: http://www.triumfant.com/

COPYRIGHT 2008 PR Newswire Association LLC
COPYRIGHT 2008 Gale, Cengage Learning

Information provided by: Findarticles.com